abstract: UNASSIGNED: The aim of this systematic review was to identify and describe brief dietary assessment tools suitable for use in clinical practice in the management of @entity2 , @entity3 and @entity4 2 @entity1 . Papers describing development of brief (<35 items) dietary assessment questionnaires, that were accessible, simple to score and assessed aspects of the diet of relevance to the conditions of interest were identified from electronic databases. The development of 35 tools was described in 47 papers. Ten tools assessed healthy eating or healthy dietary patterns, 2 assessed adherence to the Mediterranean diet, 18 assessed dietary fat intake, and 5 assessed vegetable and/or fruit intake. Twenty tools were developed in North America. Test-retest reliability was conducted on 18 tools; correlation coefficients for total scores ranged from 0.59 to 0.95. Relative validation was conducted on 34 tools. The most common reference variable was percentage energy from fat (15 tools) and correlation coefficients ranged from 0.24, P<0.001 to 0.79, P<0.002. Tools that have been evaluated for reliability and/or relative validity are suitable for guiding clinicians when providing dietary advice. Variation in study design, settings and populations makes it difficult to recommend one tool over another, although future developers can enhance the understanding and use of tools by giving clear guidance as to the strengths and limitations of the study design. When selecting a tool, clinicians should consider whether their @entity0 population is similar in characteristics to the evaluation sample.European Journal of Clinical Nutrition advance online publication, 25 February 2015; doi:10.1038/ejcn.2015.6.

title: A systematic review of brief dietary questionnaires suitable for clinical use in the prevention and management of @entity2 , @entity3 and @entity4 2 XXXX .

answer: @entity1


abstract: BACKGROUND: Racial disparity is often identified as a factor in survival from @entity0 in the United States. Current data regarding survival in @entity1 treated in the Department of Defense Military Healthcare System is lacking. METHODS: The Department of Defense Automated Central Tumor Registry (ACTUR) was queried for all @entity1 diagnosed with @entity0 from January 1, 1996 through December 31, 2008. Statistical analyses evaluated demographics, surgical treatment, @entity2 stage, and survival rates. RESULTS: There were 8,890 @entity1 meeting inclusion criteria. @entity1 who were younger, Asian American (versus white or black), lower T and/or N stage had significantly improved survival rates. Interestingly, white and black @entity1 demonstrated similar survival in this study. @entity1 with a longer period of time between diagnosis and treatment had no decrement in survival. As would be expected, @entity1 with a longer recurrence free period enjoyed longer survival. CONCLUSIONS: Survival from early stage @entity0 is equivalent between white and black @entity1 in the Department of Defense Healthcare System. This finding is contrary to reports from our civilian counterparts and may be indicative of improved access to care and overall improved @entity2 surveillance. J. Surg. Oncol.    2015 Wiley Periodicals, Inc.

title: Racial disparity in survival from early XXXX in the department of defense healthcare system.

answer: @entity0


abstract: Purpose. Our aim is to evaluate the results of treatment with computed tomography (CT) guided percutaneous radiofrequency ablation for @entity5 which were localized in a difficult area for operation. Materials and Methods. Glenoid, distal tibia, humerus shaft, proximal humerus, and in third finger of the hand proximal phalanx were involved in one @entity0 . Proximal femur was involved in three @entity0 , distal femur was involved in three @entity0 , and proximal tibia was involved in two @entity0 . 9 males and 4 females were aged 4 to 34 years (mean age: 18.5 years). All @entity0 had @entity3 and were evaluated with X-rays, CT, bone scintigraphy, and MRI. In all @entity0 , @entity4 ablation was performed with local anesthesia. The lesion heated to 90  C for 6 minutes. Results. All of the @entity0 achieved complete @entity3 relief after ablation and were fully weight bearing without any support. In all @entity0 , there was soft tissue @entity1 after the procedure. During follow-up, all @entity0 were free from the @entity3 and there was no sign about the @entity2 . There was no other complication after the process. Conclusion. CT guided RFA is a minimally invasive, safe, and cost-effective treatment for @entity5 placed in difficult area for surgery.

title: XXXX treated with radiofrequency ablation.

answer: @entity5


abstract: A severe, @entity6 that resulted in macroscopic @entity4 occurred in 8 of 20 healthy @entity1 undergoing a series of diagnostic tests. Four of the remaining 12 @entity1 had mild @entity5 consisting of @entity0 and @entity3 . Nine of the 20 @entity1 developed @entity2 after the procedures. These complications seemed associated with the radiographic technique of retrograde urethrography performed when the urinary bladder was distended. To test this hypothesis, retrograde urethrography was performed on 5 additional @entity1 . With the bladder undistended, no complications occurred. However, distention of these same @entity1 ' bladders for 1 minute or less with sterile lactated Ringer's solution administered through a Foley catheter in the penile urethra resulted in a macroscopic @entity4 in all 5 @entity1 which persisted for 24 hours. A microscopic @entity4 continued for 5 days. One @entity1 developed a @entity2 . A severe fibrinopurulent @entity6 was present at necropsy of 2 @entity1 2 days after distention. The morphologic changes in the bladder gradually diminished over 7 days, but mild @entity0 and @entity3 were still present when 2 @entity1 were necropsied, 7 days after distention. These studies indicated that retrograde urethrography in @entity1 may be complicated by @entity6 and @entity2 if performed with @entity5 .

title: Complications of XXXX during retrograde urethrography.

answer: @entity5


abstract: Case A @entity0 of Greek descent, employed as a furniture installer, aged 38 years and generally well, presented with gradual-onset, progressive, excruciating @entity6 with severe limitation of left shoulder movements. He first noticed a @entity3 around the left upper chest region, which was exacerbated by shoulder movements. Within a few hours, the @entity3 worsened and was accompanied by left shoulder stiffness. He presented twice to the emergency department within 2 days, but his condition was diagnosed as @entity3 following normal shoulder X-ray and electrocardiogram (ECG), and he was discharged with oral opioid @entity7 . He presented a third time to the emergency department with extreme upper anterior @entity6 , refractory to oral @entity7 . He was otherwise systemically well and had no fever, @entity5 . He denied @entity2 , new tattoos, intravenous drug use or @entity4 on the chest. He had not been sexually active for the @entity10 year and had been in a monogamous heterosexual relationship for 4 years prior. Examination revealed mild erythema in the left sternoclavicular region with no overt swelling or @entity4 . The upper anterior chest wall was tender to palpation, especially in the left medial clavicular region, and range of movement of the left shoulder was very limited. The initial diagnosis was pectoralis muscle tear and treatment included @entity7 and a shoulder immobiliser sling for 2 days. However, his severe @entity3 continued to worsen, despite non-opioid and opioid @entity7 , and was disproportionate to the working diagnosis. He remained afebrile throughout his hospital stay. Results of laboratory tests performed on day 3 of admission showed a white cell count (WCC) of 11.6 x 10/L (normal range 4.5-13.5 x 10/L) and @entity9 ( @entity9 ) of 119 mg/L (normal range <5 mg/L). Weight-bearing X-rays of his left shoulder and acromioclavicular joint were unremarkable. Computerised tomography (CT) chest angiography revealed no cause for @entity6 , particularly no @entity8 . Magnetic resonance imaging (MRI, Figure 1) showed severe @entity1 involving the upper chest wall, predominantly centred around the left sternoclavicular joint, and surrounding @entity1 within the pectoralis major muscle superficial to the joint, as well as deep to the joint and the sternum. No frank bony destruction was noted. Figure 1. T2 weighted images (transverse and coronal) show severe @entity1 involving the upper left chest wall, predominantly around the left sternoclavicular joint. @entity1 is present within the pectoralis major muscle superficial to the joint as well as the mediastinum deep to the joint and the sternum.

title: An uncommon cause of severe XXXX .

answer: @entity6


abstract: Although a single electrophoretically uniform antibody component with specificity for the group @entity2 may comprise the bulk of the gamma-globulin in @entity0 immunized with streptococcal vaccines, this is not always the case. Not infrequently, electrophoresis may reveal multiple antibody components. Nevertheless, it has been feasible by various preparative procedures to isolate from a single antiserum at least two antibody components with similar reactivity for the @entity2 both of which are electrophoretically monodisperse. Light chains from such antibodies reveal a restricted pattern when examined by disc electrophoresis. Antibodies to streptococcal @entity3 have been examined for their individual antigenic specificity. @entity1 were immunized with isolated Group C and Group A-variant antibodies raised in rabbits. Individual antigenic specificity of these antibodies was brought out by absorption of the goat anti-antiserum with Fr II of pooled normal @entity0 sera. Additional absorption of the goat anti-antisera with Fr II diminished but did not eliminate the reactivity for the homologous antibody. Immunoelectrophoretic studies with papain fragments of purified streptococcal antibodies localized the specificity to the Fab fragment. Specificity was not confined to the isolated light chains of the antibody.

title: The individual antigenic specificity of antibodies to streptococcal XXXX .

answer: @entity3


abstract: STUDY DESIGN: Retrospective review, full-body radiographical analysis of adult @entity0 with @entity1 ( @entity1 ). OBJECTIVE: To investigate the compensatory mechanisms involved in the sagittal plane of the body after progressive @entity1 and to study the impact of age on compensatory mechanism recruitment. SUMMARY OF BACKGROUND DATA: @entity0 with @entity1 recruit compensatory mechanisms to maintain erect posture and horizontal gaze. Mechanisms such as pelvic retroversion, knee flexion, and pelvic shift have been proposed, but how they contribute and how age affects their recruitment are poorly understood. METHODS: Retrospective review of adult @entity0 with @entity1 who underwent full-standing axis stereoradiography (EOS imaging). Radiographical measurements were performed with Surgimap. @entity0 were categorized on the basis of the mismatch between pelvic incidence (PI) and @entity3 (PI-LL). Compensatory mechanisms were normalized to each @entity0 's PI-LL and compared by mismatch groups. In addition, @entity0 were subcategorized into 2 age groups (>= 65 and <65 yr) and compared within the same groups of mismatch. RESULTS: A total of 161 @entity0 with a mean age of 62.93    12.8 years. Mean sagittal vertical axis = 62.3    61.5 mm; pelvic tilt (PT) = 29.2      8.4  ; and PI-LL = 21.0      14.9  . Mismatch groups were as follows: group 1: PI-LL 0  -10  ; group 2: 10  -20  ; group 3: 20  -30  ; and group 4: >30  . There were significant differences between all groups with regard to @entity2 ( @entity2 ), PT, knee flexion angle, and pelvic shift by analysis of variance (P < 0.001). As PI-LL increased, @entity2 and PT contribution to the compensation cascade decreased and knee flexion angle and pelvic shift contribution increased. @entity0 with PI-LL of more than 30   who were older had significantly less PT and more @entity2 than @entity0 with similar PI-LL who were younger. CONCLUSION: Spinopelvic mismatch is an important driver in @entity1 . Pelvic retroversion and flattening of @entity2 (reduction) become exhausted with increasing mismatch, at which point there seems to be a steady transfer of compensation toward significant participation of the lower limbs. Further analysis suggests differential recruitment of these compensatory mechanisms based upon age. LEVEL OF EVIDENCE: 3.

title: Recruitment of compensatory mechanisms in XXXX is age and regional deformity dependent: a full-standing axis analysis of key radiographical parameters.

answer: @entity1


abstract: The key enzyme in @entity5 (LT) biosynthesis is @entity3 (5-LO), which is expressed in myeloid cells and in B lymphocytes. There are three phosphorylation sites on 5-LO (Ser271, Ser523 and Ser663). Protein kinase A (PKA) phosphorylates 5-LO on Ser523. In this report, we demonstrate by immunoblotting that native 5-LO in @entity4 ( @entity4 ) cells (Granta519, JEKO1, and @entity8 ) and in primary chronic @entity7 cells (B-CLL) is phosphorylated on Ser523. In contrast, we could not detect phosphorylation of 5-LO on Ser523 in @entity0 granulocytes or monocytes. Phosphorylated 5-LO was purified from @entity8 cells, using an @entity1 -agarose column, and the partially purified enzyme could be dephosphorylated with alkaline phosphatase. Incubation of @entity8 cells with @entity6 or @entity2 stimulated phosphorylation at Ser523. Furthermore, FLAG-5LO was expressed in @entity8 cells, and the cells were cultivated in the presence of @entity6 . The 5-LO protein from these cells was immunoprecipitated, first with anti-FLAG, followed by anti-pSer523-5-LO. The presence of 5-LO protein in the final precipitate further supported the finding that the protein recognized by the pSer523 antibody was 5-LO. Taken together, this study shows that 5-LO in B cells is phosphorylated on Ser523 and demonstrates for the first time a chemical difference between 5-LO in myeloid cells and B cells.

title: Phosphorylation of serine 523 on XXXX in @entity0 B lymphocytes.

answer: @entity3


abstract: The key enzyme in @entity5 (LT) biosynthesis is @entity3 (5-LO), which is expressed in myeloid cells and in B lymphocytes. There are three phosphorylation sites on 5-LO (Ser271, Ser523 and Ser663). Protein kinase A (PKA) phosphorylates 5-LO on Ser523. In this report, we demonstrate by immunoblotting that native 5-LO in @entity4 ( @entity4 ) cells (Granta519, JEKO1, and @entity8 ) and in primary chronic @entity7 cells (B-CLL) is phosphorylated on Ser523. In contrast, we could not detect phosphorylation of 5-LO on Ser523 in @entity0 granulocytes or monocytes. Phosphorylated 5-LO was purified from @entity8 cells, using an @entity1 -agarose column, and the partially purified enzyme could be dephosphorylated with alkaline phosphatase. Incubation of @entity8 cells with @entity6 or @entity2 stimulated phosphorylation at Ser523. Furthermore, FLAG-5LO was expressed in @entity8 cells, and the cells were cultivated in the presence of @entity6 . The 5-LO protein from these cells was immunoprecipitated, first with anti-FLAG, followed by anti-pSer523-5-LO. The presence of 5-LO protein in the final precipitate further supported the finding that the protein recognized by the pSer523 antibody was 5-LO. Taken together, this study shows that 5-LO in B cells is phosphorylated on Ser523 and demonstrates for the first time a chemical difference between 5-LO in myeloid cells and B cells.

title: Phosphorylation of serine 523 on @entity3 in XXXX B lymphocytes.

answer: @entity0


abstract: OBJECTIVE: @entity1 is a dissociative agent often used in pediatric emergency departments for procedural sedation. Institutions commonly use either 1.5 mg/kg ( @entity3 ) or 1 mg/kg ( @entity2 ) as intravenous dosing. We sought to determine whether @entity0 receiving @entity2 require more administered doses during sedation than @entity0 receiving @entity3 . Furthermore, we examined whether differences existed between @entity2 and @entity3 in the total dosage, total mg/kg, and time to recovery. @entity0 AND METHODS: A retrospective chart review examining procedural sedations from July 2010 through December 2011 was performed for sedations using @entity2 or @entity3 . Cohorts were compared on the basis of the number of doses, mg/kg administered, total dosage (mg), and adverse events. RESULTS: A total of 346 @entity0 were included, with 159 @entity0 in @entity2 and 187 @entity0 in @entity3 . No significant differences in demographics were observed between @entity2 and @entity3 . @entity0 in @entity3 required fewer median doses of @entity1 compared with @entity2 (1.0 vs. 2.0, P=0.02). @entity2 had a higher median overall mg/kg dosage (1.71 mg/kg) than @entity3 (1.60 mg/kg) (P<0.01). @entity3 showed a decrease in the number of sedations requiring a third dose of @entity1 to complete sedation as compared with @entity2 (7.57 vs. 18.47%, P=0.002). No significant difference in adverse events was found between @entity2 and @entity3 . CONCLUSION: Sedations using @entity3 require fewer doses, lower mg/kg administered, but a higher total dose than @entity2 . No difference was found in the rate of adverse events between the groups. Our findings suggest that @entity1 sedations can be completed safely with one dose when @entity0 are initially dosed at 1.5 mg/kg.

title: A retrospective comparison of XXXX dosing regimens for pediatric procedural sedation.

answer: @entity1


abstract: AIM: @entity8 ( @entity8 ) is an @entity1 in which fragile bones readily cause @entity2 . @entity4 , @entity3 and @entity7 are uncommon cardiovascular manifestations of @entity8 . Cardiac surgery in these @entity0 carries a high risk of complications due to increased tissue and @entity5 . We describe an open heart surgery in a @entity0 with isolated @entity3 secondary to @entity8 . MATERIAL OF STUDY: A 58-year-old @entity0 was referred to our hospital for surgical correction of @entity3 . She had a past history of recurrent @entity2 , and @entity8 was diagnosed in the childhood. A standard median sternotomy was performed; the sternum was found to be thin and brittle. The native aortic valve was replaced with a size 23 mm stented aortic bioprosthesis. The sternum was closed with stainless steel wires. RESULTS: The postoperative course was uneventful, and the @entity0 was discharged home on the eighth postoperative day. We used thoracic band to avoid sternal diastasis. One year postoperatively, the echocardiogram showed a normal aortic bioprosthesis function without @entity6 . The sternum was stable without dehiscence. DISCUSSION: The mortality rate in cardiac surgery @entity0 with heritable generalized connective tissue disorders, such as @entity8 , is high. Although tissue friability had no impact on surgical outcome, it should be kept in mind when operating on @entity0 with @entity8 . CONCLUSIONS: We highlight the importance of a meticulous surgical technique, together with a strategy for management of anticipated perioperative complications to ensure a successful outcome. KEY WORDS: Aortic valve, Endocardirtis, Mitral valve, Replacement.

title: Aortic valve replacement in a XXXX with ostegenesis imperfecta A case report.

answer: @entity0


abstract: PURPOSE: To evaluate the 6-month effects of the recommended drug and light dosage in focal vascular-targeted photodynamic therapy (VTP) using TOOKAD(  ) Soluble in @entity0 with @entity1 ( @entity1 ). METHODS: We performed a pooled analysis of 117 @entity0 with @entity1 , PSA <10  ng/mL, and Gleason score  <=7 (3  +  4), from 3 studies who received a 10-min intravenous infusion of a single dose of 4  mg/kg TOOKAD(  ) Soluble, activated by a 753-nm light at 200  J/cm delivered in the prostate by transperineal fibres under transrectal ultrasound guidance. Primary endpoint was 6-month negative biopsies in the treated lobe(s). PSA was measured at month 1, 3, and 6. Magnetic resonance imaging was performed at day 7, month 3, and 6. International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) and adverse events were reported at day 7, month 1, 3, and 6. RESULTS: Month 6 negative biopsy rate was 68.4  % in the overall evaluable population (N  =  114) and 80.6  % for @entity0 treated by hemiablation with light density index (LDI)  >=   1 (N  =  67). Mean prostate necroses at week-1 were 76.5 and 86.3  %, respectively. In both groups, PSA levels at month 6 decreased by 2.0  ng/mL. Small changes from baseline for IPSS and IIEF-5 indicated a slight improvement in urinary function and a slight deterioration in sexual function. CONCLUSIONS: Focal VTP treatment with TOOKAD(  ) Soluble at 4  mg/kg and 200  J/cm resulted in a negative 6-month biopsy rate of 68.4  % for the whole population and 80.6  % for @entity0 treated by hemiablation with LDI  >=   1. The treatment was well tolerated. Two phase III studies will reach completion in early 2015.

title: TOOKAD(  ) Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of XXXX .

answer: @entity1


abstract: OBJECTIVES: Bacterial biofilms developing in the bronchial tree of @entity0 experiencing acute exacerbations of chronic @entity7 (AECBs) are suggested to cause relapses and recurrences of the disease because the matrix barrier impairs antibiotic access to the offending organisms. We examined whether bronchodilators could modulate pneumococcal biofilm development and antibiotic action using an in vitro model. METHODS: @entity1 strains from @entity0 hospitalized for AECBs and two reference strains (ATCC 49619 and R6) were screened for biofilm formation (multi-well plates; 2-11 days of growth). @entity8 and @entity4 (alone or in combination) were added at concentrations of 1.45 and 7.25 mg/L, respectively (mimicking those in the bronchial tree), and their effects were measured on biofilm formation and modulation of the activity of antibiotics [full antibiotic concentration-dependent effects (pharmacodynamic model)] with a focus on @entity6 and @entity10 . Bacterial viability and biomass were measured by the reduction of @entity9 and crystal violet staining, respectively. Release of @entity5 (from biofilm) and @entity3 activity were measured using enzymatic and HPLC-MS detection of @entity5 . RESULTS: All clinical isolates produced biofilms, but with fast disassembly if from @entity0 who had received muscarinic antagonists. @entity8 caused: (i) reduced biomass formation and faster biofilm disassembly with free @entity5 release; and (ii) a marked improvement of antibiotic activity (bacterial killing and biomass reduction). @entity4 stimulated @entity3 activity associated with improved antibiotic killing activity (reversed by @entity2 ) but modest biomass reduction. CONCLUSIONS: @entity8 and, to a lesser extent, @entity4 may cooperate with antibiotics for bacterial clearance and disassembly of pneumococcal biofilms.

title: Modulation of the activity of @entity6 and XXXX in an in vitro pharmacodynamic model of @entity1 naive and induced biofilms.

answer: @entity10


abstract: OBJECTIVES: Bacterial biofilms developing in the bronchial tree of @entity0 experiencing acute exacerbations of chronic @entity7 (AECBs) are suggested to cause relapses and recurrences of the disease because the matrix barrier impairs antibiotic access to the offending organisms. We examined whether bronchodilators could modulate pneumococcal biofilm development and antibiotic action using an in vitro model. METHODS: @entity1 strains from @entity0 hospitalized for AECBs and two reference strains (ATCC 49619 and R6) were screened for biofilm formation (multi-well plates; 2-11 days of growth). @entity8 and @entity4 (alone or in combination) were added at concentrations of 1.45 and 7.25 mg/L, respectively (mimicking those in the bronchial tree), and their effects were measured on biofilm formation and modulation of the activity of antibiotics [full antibiotic concentration-dependent effects (pharmacodynamic model)] with a focus on @entity6 and @entity10 . Bacterial viability and biomass were measured by the reduction of @entity9 and crystal violet staining, respectively. Release of @entity5 (from biofilm) and @entity3 activity were measured using enzymatic and HPLC-MS detection of @entity5 . RESULTS: All clinical isolates produced biofilms, but with fast disassembly if from @entity0 who had received muscarinic antagonists. @entity8 caused: (i) reduced biomass formation and faster biofilm disassembly with free @entity5 release; and (ii) a marked improvement of antibiotic activity (bacterial killing and biomass reduction). @entity4 stimulated @entity3 activity associated with improved antibiotic killing activity (reversed by @entity2 ) but modest biomass reduction. CONCLUSIONS: @entity8 and, to a lesser extent, @entity4 may cooperate with antibiotics for bacterial clearance and disassembly of pneumococcal biofilms.

title: Modulation of the activity of XXXX and @entity10 in an in vitro pharmacodynamic model of @entity1 naive and induced biofilms.

answer: @entity6


abstract: OBJECTIVES: Bacterial biofilms developing in the bronchial tree of @entity0 experiencing acute exacerbations of chronic @entity7 (AECBs) are suggested to cause relapses and recurrences of the disease because the matrix barrier impairs antibiotic access to the offending organisms. We examined whether bronchodilators could modulate pneumococcal biofilm development and antibiotic action using an in vitro model. METHODS: @entity1 strains from @entity0 hospitalized for AECBs and two reference strains (ATCC 49619 and R6) were screened for biofilm formation (multi-well plates; 2-11 days of growth). @entity8 and @entity4 (alone or in combination) were added at concentrations of 1.45 and 7.25 mg/L, respectively (mimicking those in the bronchial tree), and their effects were measured on biofilm formation and modulation of the activity of antibiotics [full antibiotic concentration-dependent effects (pharmacodynamic model)] with a focus on @entity6 and @entity10 . Bacterial viability and biomass were measured by the reduction of @entity9 and crystal violet staining, respectively. Release of @entity5 (from biofilm) and @entity3 activity were measured using enzymatic and HPLC-MS detection of @entity5 . RESULTS: All clinical isolates produced biofilms, but with fast disassembly if from @entity0 who had received muscarinic antagonists. @entity8 caused: (i) reduced biomass formation and faster biofilm disassembly with free @entity5 release; and (ii) a marked improvement of antibiotic activity (bacterial killing and biomass reduction). @entity4 stimulated @entity3 activity associated with improved antibiotic killing activity (reversed by @entity2 ) but modest biomass reduction. CONCLUSIONS: @entity8 and, to a lesser extent, @entity4 may cooperate with antibiotics for bacterial clearance and disassembly of pneumococcal biofilms.

title: Modulation of the activity of @entity6 and @entity10 in an in vitro pharmacodynamic model of XXXX naive and induced biofilms.

answer: @entity1


abstract: BACKGROUND: Early @entity1 shrinkage (ETS) and depth of response (DoR) predict @entity4 ( @entity4 ) in first-line trials of chemotherapy    anti- @entity3 monoclonal antibodies in metastatic @entity2 (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab ( @entity5 ) versus FOLFIRI plus @entity5 . @entity0 AND METHODS: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), @entity4 ( @entity4 ) and @entity4 were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. RESULTS: A significantly higher percentage of @entity0 in the FOLFOXIRI plus @entity5 arm achieved ETS >= 20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus @entity5 arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, @entity4 and @entity4 at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. CONCLUSION: FOLFOXIRI plus @entity5 improves ETS and DoR when compared with FOLFIRI plus @entity5 . Achieving rapid and deep @entity1 shrinkage consistently delays @entity1 progression and prolongs survival in @entity0 treated with first-line chemotherapy plus @entity5 . ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

title: Early @entity1 shrinkage and depth of response predict long-term outcome in metastatic XXXX @entity0 treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.

answer: @entity2


abstract: BACKGROUND: Early @entity1 shrinkage (ETS) and depth of response (DoR) predict @entity4 ( @entity4 ) in first-line trials of chemotherapy    anti- @entity3 monoclonal antibodies in metastatic @entity2 (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab ( @entity5 ) versus FOLFIRI plus @entity5 . @entity0 AND METHODS: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), @entity4 ( @entity4 ) and @entity4 were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. RESULTS: A significantly higher percentage of @entity0 in the FOLFOXIRI plus @entity5 arm achieved ETS >= 20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus @entity5 arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, @entity4 and @entity4 at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. CONCLUSION: FOLFOXIRI plus @entity5 improves ETS and DoR when compared with FOLFIRI plus @entity5 . Achieving rapid and deep @entity1 shrinkage consistently delays @entity1 progression and prolongs survival in @entity0 treated with first-line chemotherapy plus @entity5 . ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

title: Early XXXX shrinkage and depth of response predict long-term outcome in metastatic @entity2 @entity0 treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.

answer: @entity1


abstract: BACKGROUND: Early @entity1 shrinkage (ETS) and depth of response (DoR) predict @entity4 ( @entity4 ) in first-line trials of chemotherapy    anti- @entity3 monoclonal antibodies in metastatic @entity2 (mCRC). These associations and the predictive accuracy of response measurements for survival parameters were investigated in the phase III TRIBE trial of FOLFOXIRI plus bevacizumab ( @entity5 ) versus FOLFIRI plus @entity5 . @entity0 AND METHODS: A landmark approach was adopted to define the assessable population. The distribution of RECIST response rate, ETS and DoR was compared in the two arms. Associations between response measurements and progression-free survival (PFS), @entity4 ( @entity4 ) and @entity4 were tested by univariate and multivariate Cox models. Prediction performance of each factor was estimated by C-index. RESULTS: A significantly higher percentage of @entity0 in the FOLFOXIRI plus @entity5 arm achieved ETS >= 20%, when compared with the control arm (62.7% versus 51.9%, P = 0.025). Also the DoR was significantly higher in the triplet plus @entity5 arm (43.4% versus 37.8%, P = 0.003). Both ETS and DoR were associated with PFS, @entity4 and @entity4 at the univariate analyses and in the multivariate models stratified for other prognostic variables. Both ETS and DoR were able to predict survival as accurately as RECIST response. CONCLUSION: FOLFOXIRI plus @entity5 improves ETS and DoR when compared with FOLFIRI plus @entity5 . Achieving rapid and deep @entity1 shrinkage consistently delays @entity1 progression and prolongs survival in @entity0 treated with first-line chemotherapy plus @entity5 . ETS is a promising and valuable end point for clinical trials' design deserving further investigation.

title: Early @entity1 shrinkage and depth of response predict long-term outcome in metastatic @entity2 XXXX treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.

answer: @entity0


abstract: UNASSIGNED: @entity2 type 1 is the most common form of adult @entity3 and has the world's highest prevalence in the Saguenay-Lac-St-Jean region, due to a founder effect. This @entity1 results from an unstable CTG repeat expansion in @entity4 . This region of Canada has had a family screening and predictive testing program for this disorder since 1988. Heterozygotes for small expansions (50-100 CTG repeats) can be asymptomatic or minimally affected. The aim of this study was to assess anticipation for these individuals. At the time of this study, the molecular data of 40 individuals and their 76 affected @entity0 were available. We compared 76 parent- @entity0 pairs. Most offspring (92.1%) had a larger number of repeats than their parent and the median number of repeats in the offspring was 325 (range, 57-2000). The number of CTG repeats was significantly greater when the mutation was transmitted by a father (median, 425 repeats; range, 70-2000), than when it was transmitted by a mother (median, 200 repeats; range, 57-1400). The majority (65.8%) of @entity0 also had a more severe phenotype than their parent but the sex of the parent had no significant influence on the severity of the @entity0 's phenotype. No congenital phenotype was observed. These results confirm that anticipation is present even when the parent is heterozygous for a small CTG expansion. The parental sex has an impact on the size of the repeat in the next generation, larger increases being transmitted by males with a small expansion.    2015 Wiley Periodicals, Inc.

title: Anticipation in XXXX type 1 parents with small CTG expansions.

answer: @entity2


abstract: BACKGROUND: @entity4 ( @entity4 ) is a major cause of amputation. A clear understanding of prognostic factors for amputation is important to inform surgical decision-making, @entity0 counselling and risk stratification. The aim was to develop an understanding of prognostic factors for amputation following surgical repair of @entity4 . METHODS: A systematic review was conducted to identify potential prognostic factors. Bayesian meta-analysis was used to calculate an absolute (pooled proportion) and relative (pooled odds ratio, OR) measure of the amputation risk for each factor. RESULTS: Forty-five studies, totalling 3187 discrete @entity4 repairs, were included. The overall amputation rate was 10  0 (95 per cent credible interval 7  4 to 13  1) per cent. Significant prognostic factors for secondary amputation included: associated major soft tissue injury (26 versus 8 per cent for no soft tissue injury; OR 5  80), @entity5 (28 versus 6 per cent; OR 5  11), multiple @entity3 (18 versus 9 per cent; OR 4  85), duration of ischaemia exceeding 6   h (24 versus 5 per cent; OR 4  40), associated @entity2 (14 versus 2 per cent; OR 4  30), mechanism of injury (blast 19 per cent, blunt 16 per cent, penetrating 5 per cent), anatomical site of injury (iliac 18 per cent, popliteal 14 per cent, tibial 10 per cent, femoral 4 per cent), age over 55   years (16 versus 9 per cent; OR 3  03) and sex ( @entity0 7 per cent versus @entity0 8 per cent; OR 0  64). Shock and nerve or @entity3 were not significant prognostic factors for secondary amputation. CONCLUSION: A significant proportion of @entity0 who undergo lower extremity vascular @entity1 repair will require secondary amputation. This meta-analysis describes significant prognostic factors needed to inform surgical judgement, risk assessment and @entity0 counselling.

title: Meta-analysis of prognostic factors for amputation following surgical repair of lower extremity vascular XXXX .

answer: @entity1


abstract: UNASSIGNED: Magnetic resonance imaging (MRI) and brain volumetry allow for the quantification of changes in brain volume using automatic algorithms which are widely used in both, clinical and scientific studies. However, studies comparing the reliability of these programmes are scarce and mainly involved MRI derived from younger healthy controls. This study evaluates the reliability of frequently used @entity4 ( @entity4 , FreeSurfer, FSL) using a realistic digital brain phantom and MRI brain acquisitions from @entity0 with manifest @entity2 ( @entity2 , n=34), @entity1 ( @entity1 , n=60), and healthy subjects (n=32) matched for age and sex. Analysis of the brain phantom dataset demonstrated that @entity4 , FSL and FreeSurfer underestimate grey matter and overestimate white matter volumes with increasing noise. FreeSurfer calculated overall smaller brain volumes with increasing noise. Image inhomogeneity had only minor, non- significant effects on the results obtained with @entity4 and FreeSurfer 5.1, but had effects on the FSL results (increased white matter volumes with decreased grey matter volumes). The analysis of the @entity0 data yielded decreasing volumes of grey and white matter with progression of @entity3 independent of the method used. FreeSurfer calculated the largest grey matter and the smallest white matter volumes. FSL calculated the smallest grey matter volumes; @entity4 the largest white matter volumes. Best results are obtained with good image quality. With poor image quality, especially noise, @entity4 provides the best segmentation results. An optimised template for segmentation had no significant effect on segmentation results. While our findings underline the applicability of the programmes investigated, @entity4 may be the programme of choice when MRIs with limited image quality or brain images of elderly should be analysed.

title: Comparison of automated brain segmentation using a brain phantom and @entity0 with early @entity2 or XXXX .

answer: @entity1


abstract: UNASSIGNED: Magnetic resonance imaging (MRI) and brain volumetry allow for the quantification of changes in brain volume using automatic algorithms which are widely used in both, clinical and scientific studies. However, studies comparing the reliability of these programmes are scarce and mainly involved MRI derived from younger healthy controls. This study evaluates the reliability of frequently used @entity4 ( @entity4 , FreeSurfer, FSL) using a realistic digital brain phantom and MRI brain acquisitions from @entity0 with manifest @entity2 ( @entity2 , n=34), @entity1 ( @entity1 , n=60), and healthy subjects (n=32) matched for age and sex. Analysis of the brain phantom dataset demonstrated that @entity4 , FSL and FreeSurfer underestimate grey matter and overestimate white matter volumes with increasing noise. FreeSurfer calculated overall smaller brain volumes with increasing noise. Image inhomogeneity had only minor, non- significant effects on the results obtained with @entity4 and FreeSurfer 5.1, but had effects on the FSL results (increased white matter volumes with decreased grey matter volumes). The analysis of the @entity0 data yielded decreasing volumes of grey and white matter with progression of @entity3 independent of the method used. FreeSurfer calculated the largest grey matter and the smallest white matter volumes. FSL calculated the smallest grey matter volumes; @entity4 the largest white matter volumes. Best results are obtained with good image quality. With poor image quality, especially noise, @entity4 provides the best segmentation results. An optimised template for segmentation had no significant effect on segmentation results. While our findings underline the applicability of the programmes investigated, @entity4 may be the programme of choice when MRIs with limited image quality or brain images of elderly should be analysed.

title: Comparison of automated brain segmentation using a brain phantom and @entity0 with early XXXX or @entity1 .

answer: @entity2


abstract: UNASSIGNED: Magnetic resonance imaging (MRI) and brain volumetry allow for the quantification of changes in brain volume using automatic algorithms which are widely used in both, clinical and scientific studies. However, studies comparing the reliability of these programmes are scarce and mainly involved MRI derived from younger healthy controls. This study evaluates the reliability of frequently used @entity4 ( @entity4 , FreeSurfer, FSL) using a realistic digital brain phantom and MRI brain acquisitions from @entity0 with manifest @entity2 ( @entity2 , n=34), @entity1 ( @entity1 , n=60), and healthy subjects (n=32) matched for age and sex. Analysis of the brain phantom dataset demonstrated that @entity4 , FSL and FreeSurfer underestimate grey matter and overestimate white matter volumes with increasing noise. FreeSurfer calculated overall smaller brain volumes with increasing noise. Image inhomogeneity had only minor, non- significant effects on the results obtained with @entity4 and FreeSurfer 5.1, but had effects on the FSL results (increased white matter volumes with decreased grey matter volumes). The analysis of the @entity0 data yielded decreasing volumes of grey and white matter with progression of @entity3 independent of the method used. FreeSurfer calculated the largest grey matter and the smallest white matter volumes. FSL calculated the smallest grey matter volumes; @entity4 the largest white matter volumes. Best results are obtained with good image quality. With poor image quality, especially noise, @entity4 provides the best segmentation results. An optimised template for segmentation had no significant effect on segmentation results. While our findings underline the applicability of the programmes investigated, @entity4 may be the programme of choice when MRIs with limited image quality or brain images of elderly should be analysed.

title: Comparison of automated brain segmentation using a brain phantom and XXXX with early @entity2 or @entity1 .

answer: @entity0


abstract: OBJECTIVE: To investigate the risk factors on initial surgery in @entity1 . METHODS: The clinical data of 173 @entity0 with @entity1 who were treated during 2010 and 2014 years in the Second Affiliated Hospital of Sun Yat-Sen University, were analyzed retrospectively. The @entity0 who had received intestinal resection or whose initial symptoms occurred at least 5 years at the end of the follow-up were recruited. Montreal classification was used to evaluate lesion location and disease behavior. The risk factors of the initial surgery were analyzed by using Logistic regression model. RESULTS: Eighty-five @entity0 (49.1%) received intestinal resection in 5 years after the onset of symptoms. The result of univariate analysis showed that the probability of surgical treatment is high in @entity0 who were male and those older than 40 years at diagnosis(P<0.05). Lesions involving upper digestive tract, @entity3 and penetrating lesions were also the risk factors on initial surgery in @entity1 (P<0.05). The result of multivariate analysis showed the relative risk of initial surgery was increased in male gender(OR=2.02, 95%CI:1.04-3.92) and in those who were older than 40 years at diagnosis(OR=2.34,95%CI:1.05-5.22). However, in @entity0 with @entity1 involving colon alone, the relative risk of initial surgery was decreased(OR=0.35, 95%CI:0.13-0.97). CONCLUSION: @entity2 is the most common clinical presentation in @entity1 . Disease behavior and operation is closely related. Older than 40 years at diagnosis and male gender is high risk factor for surgery while colonic lesion alone is protective factor.

title: [Clinical presentation and risk factors for surgery in XXXX ].

answer: @entity1


abstract: BACKGROUND: Increased risk of @entity4 in @entity0 with @entity3 is well known. Medical literature also links various autoimmune conditions with @entity2 ( @entity2 ), a rarer but very heterogeneous group of generally aggressive @entity1 . METHODS: Herein, we provide a comprehensive analysis of the available peer-reviewed literature on epidemiology, clinico-laboratory features and management of @entity3 in @entity0 with @entity5 . Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to June 2014. FINDINGS: Prevalence of various hematologic and non-hematologic autoimmune conditions in @entity0 with @entity5 appears to be increased. Due to the rarity of @entity5 , scientific literature on autoimmune conditions in these @entity0 consists mainly of case series and isolated reports. CONCLUSIONS: @entity3 can develop prior to, during or after the onset of @entity5 . The diagnosis of @entity5 should prompt early recognition of certain @entity3 if clinical suspicion exists. A dysfunctional immune response in these @entity0 may be responsible for the occurrence of @entity3 . Conversely, autoimmune conditions might create a favorable milieu for @entity2 pathogenesis. Therefore, their presence should increase the suspicion of @entity5 in an appropriate clinico-laboratory context. There is need for larger studies to assess further the @entity5 - @entity3 relationship as prognosis and management of these @entity0 can be considerably affected.

title: @entity3 in @entity0 with XXXX : a comprehensive review.

answer: @entity2


abstract: BACKGROUND: Increased risk of @entity4 in @entity0 with @entity3 is well known. Medical literature also links various autoimmune conditions with @entity2 ( @entity2 ), a rarer but very heterogeneous group of generally aggressive @entity1 . METHODS: Herein, we provide a comprehensive analysis of the available peer-reviewed literature on epidemiology, clinico-laboratory features and management of @entity3 in @entity0 with @entity5 . Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to June 2014. FINDINGS: Prevalence of various hematologic and non-hematologic autoimmune conditions in @entity0 with @entity5 appears to be increased. Due to the rarity of @entity5 , scientific literature on autoimmune conditions in these @entity0 consists mainly of case series and isolated reports. CONCLUSIONS: @entity3 can develop prior to, during or after the onset of @entity5 . The diagnosis of @entity5 should prompt early recognition of certain @entity3 if clinical suspicion exists. A dysfunctional immune response in these @entity0 may be responsible for the occurrence of @entity3 . Conversely, autoimmune conditions might create a favorable milieu for @entity2 pathogenesis. Therefore, their presence should increase the suspicion of @entity5 in an appropriate clinico-laboratory context. There is need for larger studies to assess further the @entity5 - @entity3 relationship as prognosis and management of these @entity0 can be considerably affected.

title: XXXX in @entity0 with @entity2 : a comprehensive review.

answer: @entity3


abstract: BACKGROUND: Increased risk of @entity4 in @entity0 with @entity3 is well known. Medical literature also links various autoimmune conditions with @entity2 ( @entity2 ), a rarer but very heterogeneous group of generally aggressive @entity1 . METHODS: Herein, we provide a comprehensive analysis of the available peer-reviewed literature on epidemiology, clinico-laboratory features and management of @entity3 in @entity0 with @entity5 . Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to June 2014. FINDINGS: Prevalence of various hematologic and non-hematologic autoimmune conditions in @entity0 with @entity5 appears to be increased. Due to the rarity of @entity5 , scientific literature on autoimmune conditions in these @entity0 consists mainly of case series and isolated reports. CONCLUSIONS: @entity3 can develop prior to, during or after the onset of @entity5 . The diagnosis of @entity5 should prompt early recognition of certain @entity3 if clinical suspicion exists. A dysfunctional immune response in these @entity0 may be responsible for the occurrence of @entity3 . Conversely, autoimmune conditions might create a favorable milieu for @entity2 pathogenesis. Therefore, their presence should increase the suspicion of @entity5 in an appropriate clinico-laboratory context. There is need for larger studies to assess further the @entity5 - @entity3 relationship as prognosis and management of these @entity0 can be considerably affected.

title: @entity3 in XXXX with @entity2 : a comprehensive review.

answer: @entity0


abstract: UNASSIGNED: This study was conducted to calculate the peripheral dose to critical structures and assess the radiation risks from modern radiotherapy for stage IIA/IIB @entity6 . A Monte Carlo code was used for treatment simulation on a computational phantom representing an average adult. The initial treatment phase involved anteroposterior and posteroanaterior modified @entity3 -leg fields exposing para-aortic and ipsilateral iliac lymph nodes followed by a cone-down phase for nodal mass irradiation. Peripheral doses were calculated using different modified @entity3 -leg field dimensions and an extended conventional @entity3 -leg portal. The risk models of the BEIR-VII report and ICRP-103 were combined with dosimetric calculations to estimate the probability of developing stochastic effects. Radiotherapy for @entity1 with a target dose of 30   Gy resulted in a range of 23.0-603.7   mGy to non-targeted peripheral tissues and organs. The corresponding range for treatment of stage IIB disease to a cumulative dose of 36   Gy was 24.2-633.9   mGy. A dose variation of less than 13% was found by altering the field dimensions. Radiotherapy with the conventional instead of the modern modified @entity3 -leg field increased the peripheral dose up to 8.2 times. The calculated heart doses of 589.0-632.9   mGy may increase the risk for developing @entity2 whereas the testicular dose of more than 231.9   mGy may lead to a temporary @entity4 . The probability of @entity5 in the offspring of @entity1 survivors was below 0.13% which is much lower than the spontaneous mutation rate. Abdominoplevic irradiation may increase the lifetime intrinsic risk for the induction of secondary @entity1 by 0.6-3.9% depending upon the site of interest, @entity0 's age and @entity1 dose. Radiotherapy for @entity1 with restricted fields and low doses is associated with an increased morbidity. These data may allow the definition of a risk-adapted follow-up scheme for long-term testicular @entity1 survivors.

title: Radiation therapy for stage IIA and IIB XXXX : peripheral dose calculations and risk assessments.

answer: @entity6


abstract: UNASSIGNED: The risk of @entity6 ( @entity6 ) in @entity0 with @entity1 is several-fold higher than that in individuals without @entity1 . Recent studies demonstrated a high incidence of @entity6 in @entity0 with @entity9 as well as in @entity0 with solid @entity1 . The reported incidence of @entity6 in @entity3 is variable, ranging from less than 5% to 59.5%. The incidence of @entity6 is higher in @entity11 than it is in @entity5 . The incidence of @entity6 also varies according to the disease grade, the disease stage, the performance status of the @entity0 , and the site of disease. Most @entity6 cases occur at the diagnosis of @entity1 or early in the course of @entity1 treatment. An elevated incidence of @entity6 is also reported in cases of @entity8 . @entity6 occurs in approximately 5% of @entity8 @entity0 treated with conventional chemotherapy, and treatment of @entity8 @entity0 with immunomodulatory drugs (IMid)-based therapy increases the risk of @entity6 . Prophylactic @entity2 or anticoagulant is used in @entity8 @entity0 treated with IMid-based therapy. Several reports have indicated that the incidence of @entity6 is relatively low in Asian @entity0 treated with IMid-based therapy, and concomitant use of @entity10 reduces the risk of @entity6 . The incidence of @entity4 is also increased in @entity0 with @entity8 and @entity7 of undetermined significance. Further studies are needed to develop a predictive model for identifying @entity0 with @entity3 and @entity8 who are at high risk for developing @entity4 .

title: XXXX in @entity3 @entity0 and in @entity8 @entity0 .

answer: @entity4


abstract: UNASSIGNED: The risk of @entity6 ( @entity6 ) in @entity0 with @entity1 is several-fold higher than that in individuals without @entity1 . Recent studies demonstrated a high incidence of @entity6 in @entity0 with @entity9 as well as in @entity0 with solid @entity1 . The reported incidence of @entity6 in @entity3 is variable, ranging from less than 5% to 59.5%. The incidence of @entity6 is higher in @entity11 than it is in @entity5 . The incidence of @entity6 also varies according to the disease grade, the disease stage, the performance status of the @entity0 , and the site of disease. Most @entity6 cases occur at the diagnosis of @entity1 or early in the course of @entity1 treatment. An elevated incidence of @entity6 is also reported in cases of @entity8 . @entity6 occurs in approximately 5% of @entity8 @entity0 treated with conventional chemotherapy, and treatment of @entity8 @entity0 with immunomodulatory drugs (IMid)-based therapy increases the risk of @entity6 . Prophylactic @entity2 or anticoagulant is used in @entity8 @entity0 treated with IMid-based therapy. Several reports have indicated that the incidence of @entity6 is relatively low in Asian @entity0 treated with IMid-based therapy, and concomitant use of @entity10 reduces the risk of @entity6 . The incidence of @entity4 is also increased in @entity0 with @entity8 and @entity7 of undetermined significance. Further studies are needed to develop a predictive model for identifying @entity0 with @entity3 and @entity8 who are at high risk for developing @entity4 .

title: @entity4 in XXXX @entity0 and in @entity8 @entity0 .

answer: @entity3


abstract: UNASSIGNED: The risk of @entity6 ( @entity6 ) in @entity0 with @entity1 is several-fold higher than that in individuals without @entity1 . Recent studies demonstrated a high incidence of @entity6 in @entity0 with @entity9 as well as in @entity0 with solid @entity1 . The reported incidence of @entity6 in @entity3 is variable, ranging from less than 5% to 59.5%. The incidence of @entity6 is higher in @entity11 than it is in @entity5 . The incidence of @entity6 also varies according to the disease grade, the disease stage, the performance status of the @entity0 , and the site of disease. Most @entity6 cases occur at the diagnosis of @entity1 or early in the course of @entity1 treatment. An elevated incidence of @entity6 is also reported in cases of @entity8 . @entity6 occurs in approximately 5% of @entity8 @entity0 treated with conventional chemotherapy, and treatment of @entity8 @entity0 with immunomodulatory drugs (IMid)-based therapy increases the risk of @entity6 . Prophylactic @entity2 or anticoagulant is used in @entity8 @entity0 treated with IMid-based therapy. Several reports have indicated that the incidence of @entity6 is relatively low in Asian @entity0 treated with IMid-based therapy, and concomitant use of @entity10 reduces the risk of @entity6 . The incidence of @entity4 is also increased in @entity0 with @entity8 and @entity7 of undetermined significance. Further studies are needed to develop a predictive model for identifying @entity0 with @entity3 and @entity8 who are at high risk for developing @entity4 .

title: @entity4 in @entity3 @entity0 and in XXXX @entity0 .

answer: @entity8


abstract: UNASSIGNED: The risk of @entity6 ( @entity6 ) in @entity0 with @entity1 is several-fold higher than that in individuals without @entity1 . Recent studies demonstrated a high incidence of @entity6 in @entity0 with @entity9 as well as in @entity0 with solid @entity1 . The reported incidence of @entity6 in @entity3 is variable, ranging from less than 5% to 59.5%. The incidence of @entity6 is higher in @entity11 than it is in @entity5 . The incidence of @entity6 also varies according to the disease grade, the disease stage, the performance status of the @entity0 , and the site of disease. Most @entity6 cases occur at the diagnosis of @entity1 or early in the course of @entity1 treatment. An elevated incidence of @entity6 is also reported in cases of @entity8 . @entity6 occurs in approximately 5% of @entity8 @entity0 treated with conventional chemotherapy, and treatment of @entity8 @entity0 with immunomodulatory drugs (IMid)-based therapy increases the risk of @entity6 . Prophylactic @entity2 or anticoagulant is used in @entity8 @entity0 treated with IMid-based therapy. Several reports have indicated that the incidence of @entity6 is relatively low in Asian @entity0 treated with IMid-based therapy, and concomitant use of @entity10 reduces the risk of @entity6 . The incidence of @entity4 is also increased in @entity0 with @entity8 and @entity7 of undetermined significance. Further studies are needed to develop a predictive model for identifying @entity0 with @entity3 and @entity8 who are at high risk for developing @entity4 .

title: @entity4 in @entity3 XXXX and in @entity8 @entity0 .

answer: @entity0


abstract: UNASSIGNED: The risk of @entity6 ( @entity6 ) in @entity0 with @entity1 is several-fold higher than that in individuals without @entity1 . Recent studies demonstrated a high incidence of @entity6 in @entity0 with @entity9 as well as in @entity0 with solid @entity1 . The reported incidence of @entity6 in @entity3 is variable, ranging from less than 5% to 59.5%. The incidence of @entity6 is higher in @entity11 than it is in @entity5 . The incidence of @entity6 also varies according to the disease grade, the disease stage, the performance status of the @entity0 , and the site of disease. Most @entity6 cases occur at the diagnosis of @entity1 or early in the course of @entity1 treatment. An elevated incidence of @entity6 is also reported in cases of @entity8 . @entity6 occurs in approximately 5% of @entity8 @entity0 treated with conventional chemotherapy, and treatment of @entity8 @entity0 with immunomodulatory drugs (IMid)-based therapy increases the risk of @entity6 . Prophylactic @entity2 or anticoagulant is used in @entity8 @entity0 treated with IMid-based therapy. Several reports have indicated that the incidence of @entity6 is relatively low in Asian @entity0 treated with IMid-based therapy, and concomitant use of @entity10 reduces the risk of @entity6 . The incidence of @entity4 is also increased in @entity0 with @entity8 and @entity7 of undetermined significance. Further studies are needed to develop a predictive model for identifying @entity0 with @entity3 and @entity8 who are at high risk for developing @entity4 .

title: @entity4 in @entity3 @entity0 and in @entity8 XXXX .

answer: @entity0


abstract: UNASSIGNED: Hyphae of ascomycetes are compartmentalized by septa. The central pore in these septa allows for cytoplasmic streaming. However, many of these pores are closed by Woronin bodies in @entity1 , which prevents cytoplasmic mixing and thus maintains hyphal heterogeneity. Here, @entity0 uptake and transport was studied in @entity1 . @entity0 uptake was higher in the hyphal population with high transcriptional activity when compared to the population with low transcriptional activity. @entity0 was transported from the colony center to the periphery, but not vice versa. This unidirectional flow was similar in the wild-type and the   hexA strain that does not form Woronin bodies. This indicated that septal plugging by Woronin bodies does not impact long distance @entity0 transport. Indeed, the @entity0 analogue @entity2 ( @entity2 ) translocated to neighboring hyphal compartments despite Woronin body mediated plugging of the septum that separated these compartments. Notably, @entity2 accumulated in septal cross walls, indicating that intercompartmental @entity0 transport is mediated by transporters that reside in the plasma membrane lining the septal cross-wall. The presence of such transporters would thus enable selective transport between heterogeneous compartments.

title: Selective transport between heterogeneous hyphal compartments via the plasma membrane lining septal walls of XXXX .

answer: @entity1


abstract: PURPOSE: Although orthognathic surgeries focus on adjustment of @entity2 ( @entity2 ), many clinicians know by experience that the @entity1 ( @entity1 ) also is corrected after the surgery. The authors examined whether this was indeed the case by the measuring the @entity1 during the course of orthognathic treatment. Factors associated with @entity1 correction also were evaluated. @entity0 AND METHODS: In this retrospective study, clinical features, including the @entity1 , of @entity0 with @entity2 and those with facial symmetry (FS) were compared. They were outpatients of a private orthodontic dental clinic from December 2008 to March 2012. The degree of @entity1 tilt was evaluated using an interpupillary (IP) horizontal angle. The @entity1 of @entity0 with @entity2 were analyzed further before presurgical orthodontic treatment, after presurgical orthodontic treatment, after orthognathic surgery and postsurgical orthodontic treatment, and 1  year after completion of postsurgical orthodontic treatment. The @entity1 difference at each time point was analyzed using 1-way analysis of variance. An analysis of factors that influence @entity1 tilt correction was performed by linear regression. RESULTS: Thirty-one @entity0 with @entity2 and 27 with FS were evaluated. The @entity1 tilt was more profound in the @entity2 group compared with the FS group. There were more @entity0 with skeletal Class III in the @entity2 group. The degree of @entity1 tilt in the @entity2 group was decreased after orthognathic surgery and postsurgical orthodontic treatment and remained when measured 1  year later. @entity0 were less prone than @entity0 to @entity1 tilt correction by orthognathic surgery. CONCLUSION: @entity0 with @entity2 have a tilted @entity1 compared with those with FS. Orthognathic surgery for @entity2 might correct a tilted @entity1 to a lesser degree in @entity0 .

title: Natural Head Postures of @entity0 With XXXX in Frontal View Are Corrected After Orthognathic Surgeries.

answer: @entity2


abstract: PURPOSE: Although orthognathic surgeries focus on adjustment of @entity2 ( @entity2 ), many clinicians know by experience that the @entity1 ( @entity1 ) also is corrected after the surgery. The authors examined whether this was indeed the case by the measuring the @entity1 during the course of orthognathic treatment. Factors associated with @entity1 correction also were evaluated. @entity0 AND METHODS: In this retrospective study, clinical features, including the @entity1 , of @entity0 with @entity2 and those with facial symmetry (FS) were compared. They were outpatients of a private orthodontic dental clinic from December 2008 to March 2012. The degree of @entity1 tilt was evaluated using an interpupillary (IP) horizontal angle. The @entity1 of @entity0 with @entity2 were analyzed further before presurgical orthodontic treatment, after presurgical orthodontic treatment, after orthognathic surgery and postsurgical orthodontic treatment, and 1  year after completion of postsurgical orthodontic treatment. The @entity1 difference at each time point was analyzed using 1-way analysis of variance. An analysis of factors that influence @entity1 tilt correction was performed by linear regression. RESULTS: Thirty-one @entity0 with @entity2 and 27 with FS were evaluated. The @entity1 tilt was more profound in the @entity2 group compared with the FS group. There were more @entity0 with skeletal Class III in the @entity2 group. The degree of @entity1 tilt in the @entity2 group was decreased after orthognathic surgery and postsurgical orthodontic treatment and remained when measured 1  year later. @entity0 were less prone than @entity0 to @entity1 tilt correction by orthognathic surgery. CONCLUSION: @entity0 with @entity2 have a tilted @entity1 compared with those with FS. Orthognathic surgery for @entity2 might correct a tilted @entity1 to a lesser degree in @entity0 .

title: Natural Head Postures of XXXX With @entity2 in Frontal View Are Corrected After Orthognathic Surgeries.

answer: @entity0


abstract: BACKGROUND: Previous research has shown that as @entity1 age, distress decreases despite an increase in prevalence of medical comorbidity. This could be due to increased use of psychotropic medications with comorbidity. We tested this hypothesis in older adults. METHODS: Information from medical records of older adults (65 to 99  years of age) in the following groups was collected: @entity1 with @entity0 (n   =   2359), @entity1 without any @entity2 diagnosis (n   =   27,161), @entity1 with @entity3 (n   =   2686), and @entity1 without any @entity2 diagnosis (n   =   21,014). We collected fills of antidepressant or sedative medications, diagnosis of @entity4 in the year of @entity2 diagnosis, and Charlson Comorbidity Index from the year before @entity2 . RESULTS: @entity1 with @entity0 were more likely to fill psychotropic prescriptions (both ps   <   0.02) or be diagnosed with @entity4 (p   <   0.001) than @entity1 without @entity2 . @entity1 with @entity3 were more likely to fill these prescriptions or receive a diagnosis of @entity4 than @entity1 without @entity2 (ps   <   0.05). Charlson was related to increased odds of filling both types of medication in @entity1 with @entity0 and @entity1 with @entity3 (ps   <   0.001). Comorbidity was related to greater odds of receiving a @entity4 diagnosis in @entity1 with @entity3 (p   <   0.001) but not @entity1 with @entity0 (p   >   0.15). CONCLUSIONS: Older adults with @entity0 are more likely to fill psychotropic medication prescriptions and receive a @entity4 diagnosis than those without @entity2 . Comorbidity increased the likelihood of medication fills in older adults with @entity2 . As this population experiences polypharmacy, nonpharmacologic treatments for @entity4 may need to be considered.

title: Medical comorbidity and psychotropic medication fills in older adults with XXXX .

answer: @entity0


abstract: The present study was designed to determine the role of H2-receptors in the postprandial release of @entity1 -like immunoreactivity (SLI) from the gastric fundus and antrum and from the pancreas. In @entity0 subjected to laparotomy, the pylorus was bisected and a @entity4 was created, following which 250 ml 20% liver extract (LE) at pH 7 or 2 were instilled intragastrically. In the fundic vein the @entity2 in response to LE at pH 7 was 2423 plus or minus 540 pg/ml during a control infusion of saline and 4780 plus or minus 863 pg/ml during the infusion of @entity3 (1 mg/kg per h) (P less than 0.05). In the antral vein the incremental SLI in response to LE at pH 7 was 2182 plus or minus 530 pg/ml during the saline control but did not rise significantly during @entity3 infusion. In the pancreatic vein the incremental SLI level after LE at pH 7 was 1953 plus or minus 358 pg/ml in the control experiments and 4430 plus or minus 1024 pg/ml during @entity3 infusion (P less than 0.025). The incremental inferior vena cava SLI level was approximately 925 pg/ml in both groups (not significant). The instillation of LE at pH 2 during the saline control lowered fundic vein SLI by 500 pg/ml; this decline was abolished during @entity3 infusion. In the antral vein the incremental SLI level of 15 750 plus or minus 2514 pg/ml during saline was lowered to only 6728 plus or minus 2257 pg/ml during @entity3 (P less than 0.025). After LE at pH 2 the incremental pancreatic vein SLI level of 5641 plus or minus 1175 pg/ml during the control infusion was also significantly reduced to 2392 plus or minus 559 pg/ml by @entity3 (P less than 0.05). The incremental SLI in the inferior vena cava was reduced from 1270 plus or minus 280 pg/ml during saline to 680 plus or minus 190 pg/ml when @entity3 was infused (P less than 0.05). The present data suggest a histaminergic influence via stimulation of H2-receptors upon the regulation of gastric and pancreatic @entity1 release during the gastric phase of a meal.

title: Role of histamine H2-receptors in gastric and pancreatic release of XXXX -like immunoreactivity during the gastric phase of meal.

answer: @entity1


abstract: UNASSIGNED: Diagnosis early in life, sensitization, @entity2 endotypes, monitoring of disease and treatment progression are key motivations for the exploration of biomarkers for @entity5 and @entity1 . The number of genes related to @entity5 and @entity1 increases steadily, however prognostic genes have not yet entered clinical application. We hypothesize that the combination of multiple genes may generate biomarkers with prognostic potential. The current review attempts to group more than 161 different potential biomarkers involved in @entity0 to pave the way for future classifiers. The potential biomarkers are categorized into either epithelial or infiltrate-derived or mixed origin, epithelial biomarkers. Furthermore surface markers were grouped into cell-type specific categories. The current literature provides multiple biomarkers for potential @entity2 endotypes that are related to T cell phenotypes such as @entity4 , Th2, Th9, Th17, Th22 and Tregs and their lead cytokines. Eosinophilic and @entity2 endotypes are also classified by epithelium-derived @entity6 and @entity3 , respectively. There are currently about 20 epithelium-derived biomarkers exclusively derived from epithelium, which are likely to innovate biomarker panels as they are easy to sample. This article systematically reviews and categorizes genes and collects current evidence that may promote these biomarkers to become part of @entity5 or @entity1 classifiers with high prognostic value. This article is protected by copyright. All rights reserved.

title: Current and future biomarkers in XXXX .

answer: @entity1


abstract: BACKGROUND: Accurate identification and management of @entity1 is essential so that @entity0 outcomes can be improved and resources used efficaciously. OBJECTIVES: In malnourished older adults admitted to rehabilitation: 1) report the prevalence, health and aged care use, and mortality of malnourished older adults; 2) determine and compare the criterion (concurrent and predictive) validity of the Scored @entity0 -Generated Subjective Global Assessment (PG-SGA) and the Mini Nutritional Assessment (MNA) in diagnosing @entity1 ; and 3) identify the Scored PG-SGA score cut-off value associated with @entity1 . DESIGN: Observational, prospective cohort. @entity0 /SETTING: @entity0 were 57 older adults (65 years and older; mean  standard deviation age=79.1  7.3 years) from two rural rehabilitation units in New South Wales, Australia. MEASUREMENTS/STATISTICAL ANALYSIS: Scored PG-SGA; MNA; and the International Statistical Classification of Diseases and Health Related Problems, 10th revision, Australian Modification (ICD-10-AM) classification of @entity1 were compared to establish concurrent @entity1 prevalence. Length of stay, discharge location, rehospitalization, admission to a residential aged care facility, and mortality were measured to report health-related outcomes and to establish predictive validity. RESULTS: Malnutrition prevalence varied according to assessment tool (ICD-10-AM: 46%; Scored PG-SGA: 53%; MNA: 28%). Using the ICD-10-AM as the reference standard, the Scored PG-SGA ratings (sensitivity 100%, specificity 87%) and score (sensitivity 92%, specificity 84%, ROC AUC [receiver operating characteristics area under the curve]=0.910  0.038) showed strong concurrent validity, and the MNA had moderate concurrent validity (sensitivity 58%, specificity 97%, receiver operating characteristics area under the curve=0.854  0.052). The Scored PG-SGA rating, Scored PG-SGA score, and MNA showed good predictive validity. Malnutrition can increase the risk of longer rehospitalization length of stay, admission to a residential aged care facility, and discharge to hospital or residential aged care facility instead of home. CONCLUSIONS: Malnutrition prevalence in the geriatric rural rehabilitation population is high, and is associated with increased health and aged care use. The Scored PG-SGA ratings and score are suitable for nutrition assessment in geriatric rehabilitation. The MNA may be suitable for nutrition assessment in geriatric rehabilitation, but care should be taken to ensure all malnourished @entity0 are identified. Additional examination of the criterion validity of the Scored PG-SGA and MNA will lend confidence to these findings.

title: Malnutrition in Geriatric Rehabilitation: Prevalence, XXXX Outcomes, and Criterion Validity of the Scored @entity0 -Generated Subjective Global Assessment and the Mini Nutritional Assessment.

answer: @entity0


abstract: BACKGROUND: Accurate identification and management of @entity1 is essential so that @entity0 outcomes can be improved and resources used efficaciously. OBJECTIVES: In malnourished older adults admitted to rehabilitation: 1) report the prevalence, health and aged care use, and mortality of malnourished older adults; 2) determine and compare the criterion (concurrent and predictive) validity of the Scored @entity0 -Generated Subjective Global Assessment (PG-SGA) and the Mini Nutritional Assessment (MNA) in diagnosing @entity1 ; and 3) identify the Scored PG-SGA score cut-off value associated with @entity1 . DESIGN: Observational, prospective cohort. @entity0 /SETTING: @entity0 were 57 older adults (65 years and older; mean  standard deviation age=79.1  7.3 years) from two rural rehabilitation units in New South Wales, Australia. MEASUREMENTS/STATISTICAL ANALYSIS: Scored PG-SGA; MNA; and the International Statistical Classification of Diseases and Health Related Problems, 10th revision, Australian Modification (ICD-10-AM) classification of @entity1 were compared to establish concurrent @entity1 prevalence. Length of stay, discharge location, rehospitalization, admission to a residential aged care facility, and mortality were measured to report health-related outcomes and to establish predictive validity. RESULTS: Malnutrition prevalence varied according to assessment tool (ICD-10-AM: 46%; Scored PG-SGA: 53%; MNA: 28%). Using the ICD-10-AM as the reference standard, the Scored PG-SGA ratings (sensitivity 100%, specificity 87%) and score (sensitivity 92%, specificity 84%, ROC AUC [receiver operating characteristics area under the curve]=0.910  0.038) showed strong concurrent validity, and the MNA had moderate concurrent validity (sensitivity 58%, specificity 97%, receiver operating characteristics area under the curve=0.854  0.052). The Scored PG-SGA rating, Scored PG-SGA score, and MNA showed good predictive validity. Malnutrition can increase the risk of longer rehospitalization length of stay, admission to a residential aged care facility, and discharge to hospital or residential aged care facility instead of home. CONCLUSIONS: Malnutrition prevalence in the geriatric rural rehabilitation population is high, and is associated with increased health and aged care use. The Scored PG-SGA ratings and score are suitable for nutrition assessment in geriatric rehabilitation. The MNA may be suitable for nutrition assessment in geriatric rehabilitation, but care should be taken to ensure all malnourished @entity0 are identified. Additional examination of the criterion validity of the Scored PG-SGA and MNA will lend confidence to these findings.

title: Malnutrition in Geriatric Rehabilitation: Prevalence, @entity0 Outcomes, and Criterion Validity of the Scored XXXX -Generated Subjective Global Assessment and the Mini Nutritional Assessment.

answer: @entity0


abstract: OBJECTIVE: @entity7 ( @entity7 ) and @entity6 ( @entity6 ) are neural crest cell @entity2 associated with @entity9 production and assessed by a @entity10 / @entity13 measurement. This review summarizes the genetics of these @entity2 . METHODS: Case presentation, review of the relevant literature, and bullet point conclusions. RESULTS: Genetic research over the past 10 years has led to a better understanding of the pathogenesis of these @entity2 , currently associated with 20 susceptibility genes (both somatic and germ-line mutations). Although most of these genes can be divided into two clusters (clusters 1 and 2), recent data suggest that all mutations converge on the @entity4 -inducible factor signaling pathway. Most of the susceptibility genes are well characterized and associated with specific clinical presentations, including biochemical phenotype, @entity2 location and behavior, as well as @entity2 or similar characteristics. Correct and early detection of hereditary PHEO/ @entity6 is paramount, as early diagnosis leads to improved and focused treatment, along with better outcomes. However, missed or delayed diagnosis of hereditary PHEO/ @entity6 forestalls proper treatment and results in multiple, recurrent, or @entity1 and avoidable complications in some @entity0 . CONCLUSION: Early diagnosis allows prompt screening for potentially lethal @entity2 associated with specific gene mutations and makes genetic testing more readily available to first-degree and other relatives of an index @entity0 . Thus, understanding the genetics of these @entity2 is an essential part of endocrinology. ABBREVIATIONS: HIF2A = @entity4 -inducible factor 2a MAX = Myc-associated factor X MEN2 = @entity12 NF1 = @entity5 @entity6 = @entity6 PHEO = @entity7 @entity14 = @entity8 dehydrogenase complex assemble factor 2 @entity15 = transmembrane protein 127 @entity11 = @entity3 .

title: XXXX and @entity6 .

answer: @entity7


abstract: OBJECTIVE: @entity7 ( @entity7 ) and @entity6 ( @entity6 ) are neural crest cell @entity2 associated with @entity9 production and assessed by a @entity10 / @entity13 measurement. This review summarizes the genetics of these @entity2 . METHODS: Case presentation, review of the relevant literature, and bullet point conclusions. RESULTS: Genetic research over the past 10 years has led to a better understanding of the pathogenesis of these @entity2 , currently associated with 20 susceptibility genes (both somatic and germ-line mutations). Although most of these genes can be divided into two clusters (clusters 1 and 2), recent data suggest that all mutations converge on the @entity4 -inducible factor signaling pathway. Most of the susceptibility genes are well characterized and associated with specific clinical presentations, including biochemical phenotype, @entity2 location and behavior, as well as @entity2 or similar characteristics. Correct and early detection of hereditary PHEO/ @entity6 is paramount, as early diagnosis leads to improved and focused treatment, along with better outcomes. However, missed or delayed diagnosis of hereditary PHEO/ @entity6 forestalls proper treatment and results in multiple, recurrent, or @entity1 and avoidable complications in some @entity0 . CONCLUSION: Early diagnosis allows prompt screening for potentially lethal @entity2 associated with specific gene mutations and makes genetic testing more readily available to first-degree and other relatives of an index @entity0 . Thus, understanding the genetics of these @entity2 is an essential part of endocrinology. ABBREVIATIONS: HIF2A = @entity4 -inducible factor 2a MAX = Myc-associated factor X MEN2 = @entity12 NF1 = @entity5 @entity6 = @entity6 PHEO = @entity7 @entity14 = @entity8 dehydrogenase complex assemble factor 2 @entity15 = transmembrane protein 127 @entity11 = @entity3 .

title: @entity7 and XXXX .

answer: @entity6


abstract: OBJECTIVE: The aim of this study was to investigate the @entity3 ( @entity3 ) morbidity rate in the Polish population, calculated @entity1 ,000 inhabitants of a given province, taking into account the differences between urban and rural areas, gender and area of residence (province) 2008-2012. METHOD: From the NFZ IT systems information was obtained on the treatment of @entity0 who had M08 and M09 @entity2 , diseases classified elsewhere by the ICD-10 diagnosis code in the settlement report of the hospital. The number of @entity0 , their gender and age at individual diagnoses were calculated based on the PESEL number provided in the statistical reports of the @entity0 with the analysed ICD-10 diagnosis. Urban and rural cases were compared using commune @entity4 codes. The basic for classifying the @entity0 as a member of a urban or rural population was the @entity4 code of the declared place of residence. RESULTS: In Poland, the number of @entity0 suffering from @entity3 has been increasing since 2008 - from 9.2 thousand in 2008 to 11.4 thousand in 2012. The majority were @entity0 (approx. 62%). Most @entity0 were living in urban areas; in 2008, 5.9 thousand: urban areas - 64% of @entity0 and 36% of @entity0 ; 3.2 thousand: rural areas - 62% of @entity0 , 38% of @entity0 ); in 2012, 7.2 thousand - urban areas); 4.2 thousand - rural areas. The morbidity indicators ranged from 0.195 - 0.357 @entity1 ,000 inhabitants, depending on the year, gender and place of residence (province and commune).

title: Juvenile idiopathic XXXX morbidity rate in rural and urban areas of Poland 2008-2012.

answer: @entity2


abstract: Antimicrobial peptides are universal in all forms of life and are well known for their strong interaction with the cell membrane. This makes them a popular target for investigation of peptide-lipid interactions. Here we report the effect of melittin, an important antimicrobial peptide, on the dynamics of membranes based on @entity2 ( @entity1 ) lipid in both the solid gel and fluid phases. To probe the phase transition, elastic neutron intensity temperature scans have been carried out on @entity1 -based unilamellar vesicles (ULV) with and without melittin. We have found that addition of a small amount (0.2 mol%) melittin eliminates the steep fall in the elastic intensity at 296 K associated with the solid gel to fluid phase transition, which is observed for pure @entity1 vesicles. Quasielastic neutron scattering (QENS) experiments have been carried out on @entity1 ULV in the solid gel and fluid phases with and without 0.2 mol% melittin. The data analysis invariably shows the presence of lateral and internal motions of the @entity1 molecule. We found that melittin does have a profound effect on the dynamics of lipid molecules, especially on the lateral motion, and affects it in a different way, depending on the phase of the bilayers. In the solid gel phase, it acts as a plasticizer, enhancing the lateral motion of @entity1 . However, in the fluid phase it acts as a stiffening agent, restricting the lateral motion of the lipid molecules. These observations are consistent with the mean squared displacements extracted from the elastic intensity temperature scans. Their importance lies in the fact that many membrane processes, including signaling and energy transduction pathways, are controlled to a great extent by the lateral diffusion of lipids in the membrane. To investigate the effect of melittin on vesicles supplemented with @entity0 , QENS experiments have also been carried out on @entity1 ULV with @entity0 in the presence and absence of 0.2 mol% melittin. Remarkably, the effects of melittin on the membrane dynamics disappear in the presence of 20 mol% @entity0 . Our measurements indicate that the destabilizing effect of the peptide melittin on membranes can be mitigated by the presence of @entity0 . This study might provide new insights into the mechanism of action of antimicrobial peptides and their selective toxicity towards foreign microorganisms.

title: Effect of antimicrobial peptide on the dynamics of phosphocholine membrane: role of XXXX and physical state of bilayer.

answer: @entity0


abstract: BACKGROUND: Preterm @entity0 are at risk for @entity8 . No therapy exists to treat this @entity7 and subsequent long-term sequelae. We have previously shown in a well-established pre-clinical model of global @entity5 - @entity2 (HI) that mesenchymal stem cells are a promising candidate for the treatment of @entity8 . In the current study, we investigated the neuroprotective capacity of multipotent adult progenitor cells (MAPC(  )), which are adherent bone marrow-derived cells of an earlier developmental stage than mesenchymal stem cells and exhibiting more potent anti-inflammatory and regenerative properties. METHODS: Instrumented preterm @entity6 fetuses were subjected to global @entity5 - @entity2 by 25  min of umbilical cord occlusion at a gestational age of 106 (term ~147) days. During a 7-day reperfusion period, vital parameters (e.g., blood pressure and heart rate; baroreceptor reflex) and (amplitude-integrated) electroencephalogram were recorded. At the end of the experiment, the preterm brain was studied by histology. RESULTS: Systemic administration of MAPC therapy reduced the number and duration of @entity4 and prevented @entity3 after global HI. In addition, MAPC  cells prevented HI-induced microglial proliferation in the preterm brain. These anti-inflammatory effects were associated with MAPC-induced prevention of @entity1 after global HI. Besides attenuation of the cerebral inflammatory response, our findings showed that MAPC  cells modulated the peripheral splenic inflammatory response, which has been implicated in the etiology of @entity2 in the preterm brain. CONCLUSIONS: In a pre-clinical animal model MAPC cell therapy improved the functional and structural outcome of the preterm brain after global HI. Future studies should establish the mechanism and long-term therapeutic effects of neuroprotection established by MAPC  cells in the developing preterm brain exposed to HI. Our study may form the basis for future clinical trials, which will evaluate whether MAPC therapy is capable of reducing neurological sequelae in preterm @entity0 with @entity8 .

title: Multipotent adult progenitor cells for XXXX in the preterm brain.

answer: @entity2


abstract: BACKGROUND: @entity4 in bowel surgery remains a devastating complication. Various risk factors have been uncovered, however, high @entity4 rates are still being reported. This study describes the use of calcification markers of the central abdominal arteries as a prognostic factor for @entity1 . METHODS: This case-control study includes clinical data from three different hospitals. @entity3 volume and @entity3 score of the aortoiliac tract were determined by CT-scan analysis. Cases were all @entity0 with @entity4 after a left-sided @entity2 (n  =  30). Three controls were randomly matched for each case. Only @entity0 with a contrast-enhanced pre-operative CT-scan were included. RESULTS: The measurements of the @entity3 score and @entity3 volume of the different trajectories showed that there was one significant difference with regard to the right external iliac artery. Multiple regression analysis showed a significant different negative odds ratio of the presence of @entity3 in the right external iliac artery. CONCLUSION: This study demonstrates that @entity3 volume and @entity3 score of the aortoiliac trajectory does not correlate with the risk of @entity1 after a left-sided @entity2 .

title: Is aortoiliac calcification linked to XXXX ? A case-control study.

answer: @entity1


abstract: UNASSIGNED: Several recent studies report the detrimental effect of @entity2 excision on the ovarian reserve. Surgical technique and the excessive use of @entity3 could be the key factors. Single-port access laparoscopy (SPAL) @entity1 has been reported as a comparable procedure to conventional laparoscopy in terms of operative outcomes. The aim of this study was to evaluate whether the single-port surgery affects the ovarian reserve whilst performing laparoscopic @entity1 for @entity2 . This was a prospective, case-control study of 99 @entity0 with @entity2 . Forty-nine @entity0 underwent single-port cystectomy and 50 @entity0 underwent multiport laparoscopic (MPL) conventional cystectomy. The primary outcome was the assessment of the ovarian reserve. We evaluated the serum anti-Mullerian hormone (AMH) levels before, 4-6 weeks and 3 months after surgery. At T2 we performed an ultrasound assessment of the antral follicular count (AFC). We have drawn attention to a statistically significant decrease of the mean AMH value and AFC in the SPAL group at the 4-6-week and 3-month follow-up compared to the conventional laparoscopy group. In conclusion, our results suggest that SPAL cystectomy should not be recommended to @entity0 undergoing surgery for @entity2 excision who want to preserve their fertility.

title: Surgical technique of XXXX excision impacts on the ovarian reserve. Single-port access laparoscopy versus multiport access laparoscopy: a case control study.

answer: @entity2


abstract: OBJECTIVES: Thoughts of historical loss (i.e., the loss of culture, land, and @entity0 as a result of colonization) are conceptualized as a contributor to the contemporary distress experienced by North American Indigenous populations. Although discussions of historical loss and related constructs (e.g., historical trauma) are widespread within the Indigenous literature, empirical efforts to understand the consequence of historical loss are limited, partially because of the lack of valid assessments. In this study we evaluated the longitudinal measurement properties of the Historical Loss Scale (HLS)-a standardized measure that was developed to systematically examine the frequency with which Indigenous individuals think about historical loss-among a sample of North American Indigenous adolescents. We also test the hypothesis that thoughts of historical loss can be psychologically distressing. METHODS: Via face-to-face interviews, 636 Indigenous adolescents from a single cultural group completed the HLS and a measure of @entity1 at 4 time-points, which were separated by 1- to 2-year intervals (M age = 12.09 years, SD = .86, 50.0% @entity0 at baseline). RESULTS: Responses to the HLS were explained well by 3-factor (i.e., cultural loss, loss of @entity0 , and cultural mistreatment) and second-order factor structures. Both of these factor structures held full longitudinal metric (i.e., factor loadings) and scalar (i.e., intercepts) equivalence. In addition, using the second-order factor structure, more frequent thoughts of historical loss were associated with increased @entity1 . CONCLUSIONS: The identified 3-factor and second-order HLS structures held full longitudinal measurement equivalence. Moreover, as predicted, our results suggest that historical loss can be psychologically distressing for Indigenous adolescents. (PsycINFO Database Record

title: The Historical Loss Scale: Longitudinal Measurement Equivalence and Prospective Links to XXXX Among North American Indigenous Adolescents.

answer: @entity1


abstract: BACKGROUND: The cytologic diagnosis obtained by brushing or biopsy in @entity1 is considered to be highly specific but poorly sensitive. The diagnostic association of biliary brushing and bile exfoliate cytology has been suggested but is rarely performed in clinical practice. The objective of this study was to assess the diagnostic performance of bile aspiration associated with biliary brushing during therapeutic endoscopic retrograde cholangiopancreatography (ERCP). METHODS: From 2004 to 2009, 239 consecutive @entity0 who underwent ERCP were included in the study. The biliary strictures were considered clinically benign in 26% of @entity0 , uncertain in 25%, and malignant in 49%. The 298 cytologic samples collected were divided in 3 groups: bile aspiration alone (26%), biliary brushing alone (20%), and bile aspiration combined with brushing (54%). The definitive diagnosis of @entity1 was obtained by biopsy, surgery, and fine-needle aspiration or was determined by an unfavorable disease course. RESULTS: The cytologic diagnoses were as follows: 149 samples were benign (50%), 114 were malignant (38%), 34 had atypia (12%), and 1 had no diagnostic value. The procedure output values were as follows: for bile aspiration alone, sensitivity was 56.4%, specificity was 93.9%, the positive predictive value ( @entity4 ) was 91.7%, and the negative predictive value (NPV) was 64.6%; for brushing alone, sensitivity was 62.5%, both specificity and the @entity4 were 100%, and the NPV was 73%; and, for bile aspiration and brushing combined, sensitivity was 81%, both specificity and the @entity4 were 100%, and the NPV was 75%. CONCLUSIONS: For @entity0 who have symptomatic @entity3 , bile aspiration during ERCP is a simple and safe procedure. Bile aspiration combined with brushing significantly increases the yield of cytology for @entity1 (sensitivity, 81%), particularly in @entity2 . @entity1 ( @entity1 Cytopathol) 2015.    2015 American @entity1 Society.

title: Monocentric study of bile aspiration associated with biliary brushing performed during endoscopic retrograde cholangiopancreatography in 239 @entity0 with symptomatic XXXX .

answer: @entity3


abstract: BACKGROUND: The cytologic diagnosis obtained by brushing or biopsy in @entity1 is considered to be highly specific but poorly sensitive. The diagnostic association of biliary brushing and bile exfoliate cytology has been suggested but is rarely performed in clinical practice. The objective of this study was to assess the diagnostic performance of bile aspiration associated with biliary brushing during therapeutic endoscopic retrograde cholangiopancreatography (ERCP). METHODS: From 2004 to 2009, 239 consecutive @entity0 who underwent ERCP were included in the study. The biliary strictures were considered clinically benign in 26% of @entity0 , uncertain in 25%, and malignant in 49%. The 298 cytologic samples collected were divided in 3 groups: bile aspiration alone (26%), biliary brushing alone (20%), and bile aspiration combined with brushing (54%). The definitive diagnosis of @entity1 was obtained by biopsy, surgery, and fine-needle aspiration or was determined by an unfavorable disease course. RESULTS: The cytologic diagnoses were as follows: 149 samples were benign (50%), 114 were malignant (38%), 34 had atypia (12%), and 1 had no diagnostic value. The procedure output values were as follows: for bile aspiration alone, sensitivity was 56.4%, specificity was 93.9%, the positive predictive value ( @entity4 ) was 91.7%, and the negative predictive value (NPV) was 64.6%; for brushing alone, sensitivity was 62.5%, both specificity and the @entity4 were 100%, and the NPV was 73%; and, for bile aspiration and brushing combined, sensitivity was 81%, both specificity and the @entity4 were 100%, and the NPV was 75%. CONCLUSIONS: For @entity0 who have symptomatic @entity3 , bile aspiration during ERCP is a simple and safe procedure. Bile aspiration combined with brushing significantly increases the yield of cytology for @entity1 (sensitivity, 81%), particularly in @entity2 . @entity1 ( @entity1 Cytopathol) 2015.    2015 American @entity1 Society.

title: Monocentric study of bile aspiration associated with biliary brushing performed during endoscopic retrograde cholangiopancreatography in 239 XXXX with symptomatic @entity3 .

answer: @entity0


abstract: BACKGROUND: The major clinical challenge in the treatment of high-grade serous @entity2 (HGSOC) is the development of progressive resistance to @entity3 -based chemotherapy. The objective of this study was to determine whether @entity1 genetic heterogeneity resulting from @entity6 and the emergence of @entity1 populations in HGSOC was associated with the development of resistant disease. METHODS AND FINDINGS: Evolutionary inference and phylogenetic quantification of heterogeneity was performed using the MEDICC algorithm on high-resolution whole genome copy number profiles and selected genome-wide sequencing of 135 spatially and temporally separated samples from 14 @entity0 with HGSOC who received @entity3 -based chemotherapy. Samples were obtained from the clinical CTCR-OV03/04 studies, and @entity0 were enrolled between 20 July 2007 and 22 October 2009. Median follow-up of the cohort was 31 mo (interquartile range 22-46 mo), censored after 26 October 2013. Outcome measures were @entity5 ( @entity5 ) and progression-free survival (PFS). There were marked differences in the degree of @entity6 ( @entity6 ) between @entity0 (median 0.74, interquartile range 0.66-1.15), and dichotimization by median @entity6 showed worse survival in @entity6 -high cases (PFS 12.7 versus 10.1 mo, p = 0.009; @entity5 42.6 versus 23.5 mo, p = 0.003). Bootstrap analysis with resampling showed that the 95% confidence intervals for the hazard ratios for PFS and @entity5 in the @entity6 -high group were greater than 1.0. These data support a relationship between heterogeneity and survival but do not precisely determine its effect size. Relapsed tissue was available for two @entity0 in the @entity6 -high group, and phylogenetic analysis showed that the prevalent clonal population at clinical recurrence arose from early divergence events. A subclonal population marked by a @entity4 deletion showed a progressive @entity1 allele fraction during chemotherapy. CONCLUSIONS: This study demonstrates that quantitative measures of @entity1 heterogeneity may have predictive value for survival after chemotherapy treatment in HGSOC. @entity1 populations are present in pre-treatment biopsies in HGSOC and can undergo expansion during chemotherapy, causing clinical relapse.

title: Spatial and temporal heterogeneity in high-grade serous XXXX : a phylogenetic analysis.

answer: @entity2